Results 221 to 230 of about 101,286 (277)

Pembrolizumab-Induced Aplastic Anemia Successfully Treated With Thrombopoietin Receptor Agonist in a Patient With Lung Adenocarcinoma: A Case Report and Literature Review. [PDF]

Cureus
Namba K, Isobe K, Nakao S, Hiruta N, Wakabayashi H.   +4 more
europepmc   +1 more source

Deep Dermal and Subcutaneous Deposits in Thin Melanoma: A Cautionary Tale

Journal of Cutaneous Pathology, Volume 53, Issue 3, Page 224-229, March 2026.
ABSTRACT Melanoma microsatellites are peritumoral metastatic deposits and surrogates for potentially aggressive biological behavior. Their presence indicates clinical stage III disease. They are rarely reported in association with thin primary tumors (< 1.0 mm, pT1).
Angela Cheng, Jennette Gruchy, Ariel Burns, Richard Langley, Jason Williams, Ryan DeCoste   +5 more
wiley   +1 more source

Targeting the Notch1‐YY1‐ICAM1 Signaling Axis Enhances the Efficacy of Immunotherapy in HCC by Activating CD8+ T‐Cell‐Driven Cancer Cell Pyroptosis

Advanced Science, Volume 13, Issue 7, 3 February 2026.
In hepatocellular carcinoma (HCC), aberrantly activated Notch1 signaling induces its target gene YY1, which impairs immunotherapy efficacy by suppressing tumor cell‐ICAM1‐driven T cell activation and the mediated pyroptosis of T cells against tumor cells.
Ke Zhu, Fa‐Peng Zhang, Chao Qin, Zhi‐Xiao Song, Cai‐Ni Yang, Shu‐Sheng Lin, Xian‐Huan Yu, Wen‐Rui Wu, Chao‐Qun Liu, Chao Liu, Lei‐Bo Xu   +10 more
wiley   +1 more source

Prognostic Value of ¹⁸F-FDG PET/CT-Derived Secondary Lymphoid Organ Ratios and Hematologic Inflammation Markers in Advanced Non-Small Cell Lung Cancer Treated with Nivolumab. [PDF]

J Clin Med
Kocaaslan E, Güren AK, Akagündüz F, Demirel A, Tunç MA, Paçacı B, Ağyol Y, Erel P, Çelebi A, Işık S, Çoban E, Demircan NC, Özgüven S, Balaban Genç ZC, Majidova N, Sever N, Sarı M, Köstek O, Bayoğlu IV.   +18 more
europepmc   +1 more source

Comparative analysis of the characteristics and trends of adverse drug reaction reports from patients in Japan and the Japanese Adverse Drug Event Report database

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 515-524, February 2026.
Aims Spontaneous reporting of adverse drug reactions (ADR) after a product has reached the market is essential for drug safety. This study analysed patient ADR reports and compared them with reports from the Japanese Adverse Drug Event Report (JADER) database to identify differences and trends.
Masami Tsuchiya, Ryohkan Funakoshi, Koichi Masuyama, Nariyasu Mano, Satoko Hori, Taku Obara   +5 more
wiley   +1 more source

Phase 1 study evaluating the safety, preliminary efficacy, and pharmacodynamics of recombinant interleukin-15 in combination with nivolumab and ipilimumab in patients with refractory cancers. [PDF]

J Immunother Cancer
Ahmed J, O'Sullivan Coyne G, Rubinstein LV, Shin SJ, Takebe N, Bruns A, Augustine B, Mukherjee J, Ma N, Fino K, Fung KL, Ferry-Galow KV, Johnson BC, Parchment RE, Streicher H, Doroshow JH, Chen AP.   +16 more
europepmc   +1 more source

Machine learning methods for predicting adverse drug events: A systematic review

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 422-444, February 2026.
Abstract Predicting adverse drug events (ADEs) in outpatient settings is crucial for improving medication safety, identifying high‐risk patients and reducing health‐care costs. While traditional methods struggle with the complexity of health‐care data, machine learning (ML) models offer improved prediction capabilities; however, their effectiveness in ...
Niaz Chalabianloo, Fatemeh Ahmadi, Mohammad Ali Omrani, Sheikh S. Abdullah, Neda Rostamzadeh, Atefeh Jafari, Lujain Izzedin, Kamran Sedig, Flory T. Muanda   +8 more
wiley   +1 more source

Targeted therapies and PARPi therapy response following ICI therapy failure in advanced melanoma: a case series. [PDF]

Melanoma Manag
Nassief G, Morecroft R, Phillipps J, Chen D, Ansstas G.   +4 more
europepmc   +1 more source

An Anoikis Resistance Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Blockades in Gastric Cancer

Cancer Innovation, Volume 5, Issue 1, February 2026.
Gastric cancer (GC) has high global incidence and mortality, with most cases diagnosed at advanced stages. Immunotherapy, particularly immune checkpoint blockers (ICBs), has shown promise, but not all patients benefit. This study applied consensus clustering based on anoikis‐related genes (ANRGs) to classify GC into two subclusters.
Xing Cai, Jinru Yang, Fangyuan Zhang, Fuwang Xu, Yuan Fang, Zongbi Yi   +5 more
wiley   +1 more source

Nivolumab plus chemotherapy in metastatic gastric cancer with low combined positive score. [PDF]

Therap Adv Gastroenterol
Kim J, Kim C, Shin JE, Lim SH, Lee J, Kim ST.   +5 more
europepmc   +1 more source